Physician profile
Othoniel Castro
NPI 1750380242
$454.15
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $121 · 2021: $39.89 · 2022: $90.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103.41 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $101.50 | 2019 | |
| Akcea Therapeutics, INC. | $62.56 | 2020 | |
| Emd Serono, INC. | $48.77 | 2019 | |
| Allergan, INC. | $46.87 | 2020-2021 | |
| Ge Healthcare | $29.10 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $23.74 | 2020 | |
| Acorda Therapeutics, INC | $22.99 | 2019 | |
| Celgene Corporation | $15.21 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Othoniel Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.